Core Viewpoint - A securities class action lawsuit has been filed against MicroStrategy Incorporated, alleging that the company made materially false and misleading statements regarding its business and operations during the specified Class Period from April 30, 2024, to April 4, 2025 [1][2]. Group 1: Allegations Against MicroStrategy - The lawsuit claims that the anticipated profitability of MicroStrategy's bitcoin-focused investment strategy was overstated [2]. - It is alleged that the risks associated with bitcoin's volatility and potential losses on digital assets were understated [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the Class Period [2]. Group 2: Lead Plaintiff Process - Investors in MicroStrategy have until July 15, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The lead plaintiff has the authority to select counsel to represent the class, subject to court approval [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging investors who have suffered losses to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Centene Corporation (“Centene” or the “Company”) (NYSE: CNC) securities between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants created the false impression that ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 22, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Red Cat securities between March 18, 2022, and January 15, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Red Cat Holdings made false and misleading statements regarding the production capacity of its Salt Lake City Facility and the value of the SRR Program's Tranche 2 contract, leading to investor damages when the truth was revealed [4].

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repr ...

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...

RADNOR, Pa., July 8, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Sarepta losses, ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., July 8, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified Holdings (NYSE: CODI) between March 1, 2023, and May 7, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Compass securities you may be entitled to compensation without payment of any out of ...

PHILADELPHIA, July 7, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repre ...

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process for Investors - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].